BL0020 for small cell lung cancer after EGFR therapy
Part of Cancer, Lungs & breathing clinical trials.
This study tests an investigational drug called BL0020 for people whose non-small cell lung cancer has changed into small cell lung cancer after treatment with EGFR inhibitors. The goal is to see if BL0020 can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You were first diagnosed with EGFR-mutated non-small cell lung cancer, and it has now transformed into small cell lung cancer after EGFR inhibitor treatment.
- You have not had chemotherapy for small cell lung cancer, or you have only had platinum-based chemotherapy and it stopped working.
- You are able to care for yourself (ECOG score 0 or 1).
- You have a life expectancy of at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (BL0020) combined with an immunotherapy drug (toripalimab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new drug combination—BL-B01D1 plus a PD-1 immunotherapy—for people who have just been diagnosed with extensive-stage small cell lung cancer and have not had any prior treatment for it. The goal is to see if this combination can help shrink or control the cancer better than standard therapy.
This study tests a new drug, MRG003, for people with a type of lung cancer called small cell lung cancer that has spread or come back after earlier treatment. The goal is to see if this drug can help shrink tumors or slow the cancer's growth.
This trial tests a new drug, BL-M14D1, for people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have no standard treatment. The goal is to see if the drug is safe and possibly effective.
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
Hear when a new Small Cell Carcinoma of Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.